Search research articles
Contact Us
Filters
Showing results (661-670 of 721) with videos related to
Page
of 73
Sort By:
The New England Journal of Medicine
|
June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann de Bono, Kim N Chi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 8, 2024
Diagnostic Accuracy of <sup>68</sup>Ga-FAPI Versus <sup>18</sup>F-FDG PET in Patients with Various Malignancies
Nader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 19, 2024
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0
Nathalie L Albert, Matthias Preusser, Tatjana Traub-Weidinger, et al.
European Urology Oncology
|
June 13, 2022
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy
Stefano Fanti, Alberto Briganti, Louise Emmett, et al.
Cancer Cell
|
April 13, 2016
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Wei Wei, Young Shik Shin, Min Xue, et al.
JAMA Oncology
|
September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial
Thomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
Neuro-Oncology Advances
|
October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Hypertension (Dallas, Tex. : 1979)
|
December 28, 2017
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma
Britta Heinze, Carmina T Fuss, Paolo Mulatero, et al.
Cancer Medicine
|
April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging Analysis
Lazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Page
of 73
Search research articles
Search
Showing results (661-670 of 721) with videos related to
Sort By:
Page
of 73
The New England Journal of Medicine
|
June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann de Bono, Kim N Chi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 8, 2024
Diagnostic Accuracy of <sup>68</sup>Ga-FAPI Versus <sup>18</sup>F-FDG PET in Patients with Various Malignancies
Nader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 19, 2024
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0
Nathalie L Albert, Matthias Preusser, Tatjana Traub-Weidinger, et al.
European Urology Oncology
|
June 13, 2022
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy
Stefano Fanti, Alberto Briganti, Louise Emmett, et al.
Cancer Cell
|
April 13, 2016
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Wei Wei, Young Shik Shin, Min Xue, et al.
JAMA Oncology
|
September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial
Thomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
Neuro-Oncology Advances
|
October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Hypertension (Dallas, Tex. : 1979)
|
December 28, 2017
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma
Britta Heinze, Carmina T Fuss, Paolo Mulatero, et al.
Cancer Medicine
|
April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging Analysis
Lazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Page
of 73